Form 4 for AXGN Axogen, Inc.
Accepted 2026-08-12 16:13:23 ET · period of report 2026-08-10 · accession 0000805928-26-000099 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-12 16:13 | 2026-08-10 | AXGN | Began Marc A | EVP, GC | M - OptEx | $8.16 | +67.5K | 117.6K | +135% | +$550.8K |
| DT | 2026-08-12 16:13 | 2026-08-10 | AXGN | Began Marc A | EVP, GC | S - Sale+OE | $47.34 | -67.5K | 50.1K | -57% | -$3.20M |
| DT | 2026-08-12 16:13 | 2026-08-10 | AXGN | Began Marc A | EVP, GC | M - OptEx | $0.00 | -67.5K | 22.5K | -75% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-10 | M | A | 67,500 | $8.16 | 117,635 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-10 | S | D | 67,500 | $47.34 | 50,135 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026. (F2) The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2026-08-10 | M | D | 67,500 | $0.00 | 22,500 | D | $8.16 · — to 2033-03-01 | 67,500 Common Stock | (F3) All shares of Axogen Inc. common stock underlying the stock option grant will be fully vested on March 1, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate stock options vest on March 1, 2025 (24 months from the grant date) and an additional 12.5% of the aggregate stock options vest each 6 months thereafter. |